Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2021-11-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
可转换公司债券付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on convertible bonds issued by the company. It details the bond terms, interest rates, payment dates, tax implications, and related procedural information. It does not contain financial statements or comprehensive financial performance data. The document is a formal notice about bond interest payment, which fits the category of Capital/Financing Update (CAP) as it relates to the company's financing instruments and their servicing.
2021-11-24 Chinese
关于董事会秘书、财务总监增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding the increase in shareholding by a company director, specifically the board secretary and financial director, who purchased additional shares of the company. It details the number of shares bought, the price, the date, and compliance with relevant securities laws and regulations. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of 'Director's Dealing' (DIRS). The document is short and focused solely on this insider transaction, with no financial statements or other report content.
2021-11-18 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2021 年第三季度报告" which translates to "2021 Third Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter of 2021. The document includes unaudited financial statements and management assurances about the accuracy and completeness of the quarterly report. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-29 Chinese
可转债转股结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the results of convertible bond conversions and the resulting changes in share capital for Lingkang Pharmaceutical Group Co., Ltd. It details the amount of bonds converted into shares during a specific period, the remaining unconverted bonds, and the changes in the company's share capital. The document includes regulatory approval references and specific bond codes but does not contain comprehensive financial statements or detailed financial performance data. It is a formal disclosure of share capital changes due to bond conversions, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other types of filings.
2021-10-08 Chinese
关于控股股东股票质押式回购交易延期购回及部分购回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of a stock pledge repurchase transaction by the controlling shareholder and partial repurchase of shares. It details the number of shares pledged, the extension of the pledge period, and the impact on the company. There is no financial statement or detailed financial analysis present. The document is a regulatory announcement about share pledge and repurchase activities, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is Capital/Financing Update (CAP).
2021-09-27 Chinese
关于控股股东股票质押式回购交易延期购回及部分解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of a stock pledge repurchase transaction by the controlling shareholder and partial release of pledged shares. It contains detailed information about share pledges, percentages, and financing arrangements but does not include financial statements or comprehensive financial data. The document is a regulatory announcement about financing activities related to share pledges and does not qualify as a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2634 characters, which is typical for an announcement rather than a full report.
2021-09-13 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.